Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET

Company Participants

Charles Liles - Head, Corporate Communications and Investor Relations

Bassil Dahiyat - President and Chief Executive Officer

Nancy Valente - Chief Development Officer

John Desjarlais - Chief Scientific Officer

John Kuch - Chief Financial Officer

Conference Call Participants

Edward Tenthoff - Piper Sandler

Dane Leone - RJS

Etzer Darout - BMO Capital Markets

Alec Stranahan - Bank of America

Jerry Gong - Mizuho

Brian Cheng - JPMorgan

Operator

Good afternoon and thank you for standing by. Welcome to Xencor’s Third Quarter 2023 Conference Call. Please be advised that this call is going to be recorded at the company’s request. Now, I would like to turn the call over to your speaker today, Charles Liles, Head of Corporate Communications and Investor Relations. Go ahead, Charles.

Charles Liles

Thank you and good afternoon. Earlier today, we issued a press release, which outlines the topics we plan to discuss today. It’s available on www.xencor.com. Providing comments on the call is Bassil Dahiyat, President and Chief Executive Officer; and Nancy Valente, Chief Development Officer. Afterwards, we will open up the call for your questions, and we’ll be joined by John Desjarlais, Chief Scientific Officer; and John Kuch, Chief Financial Officer.

Before we begin, I would like to remind you that during the course of this conference call, Xencor management may make forward-looking statements, including statements regarding the company’s future financial and operating results, future market conditions, plans and objectives of management, future operations, company’s partnering efforts, capital requirements, future product offerings and research and development programs. These forward-looking statements are not historical facts, but rather are based on our current expectations and beliefs and are based on information currently available to us. The outcome of the events described in these forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including, but not limited to, those factors contained in the Risk Factors section of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q.

With that, I will pass the call over to Bassil.

Bassil Dahiyat

Thanks, Charles. At Xencor, we are advancing a broad internal development portfolio of engineered antibody based therapeutics in oncology and autoimmune disease that we have built with our array of modular, continually advancing XmAb protein engineering tools. We are taking multiple simultaneous shots on goal in the clinic and we use emerging data from clinical studies to guide which programs we advance, which we terminate and which we partner. A stringent review of this data and the status of competitors, allows us to prudently focus our resources and cash on programs with the greatest potential.